Prohledat tento blog

Finální analýza celkového přežití ve studii Cleopatra - ESMO 2014

Konečná analýza dat ze studie fáze III CLEOPATRA, prezentovaná na kongresu ESMO 2014 prokázala, že nemocní, kteří nebyli dříve léčeni pro HER2-pozitivní metastazující karcinom prsu, dosáhli mediánu celkového přežití 56,5 měsíců při léčbě Perjetou, Herceptinem a docetaxelem, ve srovnání se 40,8 měsíci při léčbě Herceptinem a docetaxelem. Režim s Perjetou prodloužil celkové přežití u nemocných s HER2 pozitivním karcinomem prsu o 15,7 měsíců, ve srovnání se současným standardem léčby, Herceptinem s chemoterapií.

Zdroj: Mojemedicina.cz

Periductal stromal tumor of the breast with synchronous bilateral breast cancer

We report on a case of low-grade periductal stromal tumor of the breast with synchronous bilateral breast carcinoma. A 45-year-old woman came to our Hospital because of a palpable mass of the right breast. An approximately 5-cm mass was palpated in the upper right breast. The mammographic and sonographic findings of the palpable mass suggested the possibility of hamartoma. A 1.3-cm, irregular mass with microcalcifications was also detected in the upper outer quadrant of the right breast and a 1.3-cm irregular mass was detected in the upper outer quadrant of the left breast. Core-needle biopsy revealed bilateral breast carcinoma. The patient underwent bilateral breast-conserving surgery, including the excision of the large palpable mass in the right breast. The palpable mass in the right breast was confirmed as low-grade periductal stromal tumor and there were bilateral invasive ductal carcinomas in both upper outer breast quadrants. After surgery, the patient received adjuvant chemotherapy. At 16 months of follow-up, no recurrence was observed.

from: Department of Radiology, Chonnam National University Medical School, Chonnam National University Hwasun Hospital, Hwasun-gun, Jeollanam-do, Republic of Korea.
as reported in: Ki SY, Lim HS, Lee JS, Park SY, Yim NY, Heo SH, Park MH, Cho JS, Shin SH. Anticancer Res.. 2014 Jul:34(7):3635-9

Zdroj:Dgcases

First report of trastuzumab treatment after postoperative Takotsubo cardiomyopathy

Trastuzumab is a humanized monoclonal antibody used for the treatment of HER2-positive breast cancer. Cardiotoxicity is a well-known adverse event of trastuzumab use but little has been documented regarding its use in patients with a history of cardiac disease. We describe a case in which trastuzumab treatment was administered to a 40-year-old female patient with early breast cancer after acute heart failure secondary to postoperative Takotsubo cardiomyopathy. After one year of follow-up with close monitoring by echocardiography, there have been no heart-related symptoms. Additional surgery was performed because of positive resection margins at first surgery, without complications, despite the risk of recurrence of Takotsubo cardiomyopathy. Trastuzumab can be safely administered after acute heart failure secondary to postoperative Takotsubo cardiomyopathy.


from: Department of Medical Oncology, Civil Hospital, Strasbourg, France.
as reported in: Burgy M, Brossat H, Barthelemy P, Imperiale A, Trinh A, Hazam CA, Bergerat JP, Mathelin C. Anticancer Res.. 2014 Jul:34(7):3579-82.

Zdroj: Dgcases


Glycogen rich clear cell karcinom prsu

Poznámky  vzácný histologický typ karcinomu prsu  tvoří 1,4-3% všech případů karcinomu prsu obecně má špatnou prognózu prognóza se v...